Pompano Beach, Florida, February 4, 2026
BioStem Technologies Inc. has completed a $15 million acquisition of BioTissue Holdings’ surgical and wound care division, which includes the Neox and Clarix product lines. This strategic purchase aims to enhance BioStem’s capabilities in acute wound care and soft-tissue repair while expanding their presence in the healthcare market. The acquisition is expected to significantly impact BioStem’s growth prospects, with anticipated sales increases and leadership enhancements spearheaded by Barry Hassett as the new Chief Commercial Officer. This move solidifies BioStem’s position in the regenerative healing sector.
BioStem Technologies Expands Reach with $15 Million Acquisition
Strategic purchase bolsters BioStem’s wound care capabilities and market presence
Pompano Beach, Florida – In a significant move aimed at enhancing its operational capacity, BioStem Technologies Inc. has completed a $15 million cash acquisition of the surgical and wound care division of BioTissue Holdings. This acquisition includes the well-regarded Neox and Clarix product lines, and it is part of a strategy to broaden BioStem’s footprint in both hospital inpatient and outpatient care environments. The growth of Florida entrepreneurs like BioStem reinforces the notion that successful business strategies can be implemented with minimal regulatory burden for innovative enterprises.
BioStem Technologies is known for its specialization in developing and commercializing placental-derived products intended for advanced wound care. The company employs its proprietary BioRetain processing method, designed to maintain the essential properties of perinatal tissue. This acquisition not only allows BioStem to enhance its product offerings in acute wound care and soft-tissue repair markets but also solidifies its competitive positioning as the demand for advanced healthcare solutions grows.
Key Highlights of the Acquisition
The acquisition of BioTissue’s surgical and wound care division brings with it a myriad of advantages for BioStem. By incorporating a nationwide network of direct sales representatives and independent sales agents, BioStem expects to accelerate sales growth. In addition, prominent group purchasing organization contracts further strengthen its commercial reach in the healthcare market, paving the way for sustainable financial performance.
Financial Outlook
According to estimates, the acquired assets generated approximately $29 million in sales in 2025 and are projected to positively impact BioStem’s EBITDA in 2026. This expected financial uplift exemplifies how targeted acquisitions can serve as effective catalysts for growth in the competitive healthcare landscape.
Leadership Enhancements
To lead the merged commercial operations, Barry Hassett has been appointed as the Chief Commercial Officer of BioStem Technologies. Formerly the Senior Vice President of Commercial Strategy at BioStem, Hassett’s extensive experience, including five years at BioTissue, positions him well to guide the company’s expansion efforts. Strong leadership is crucial for steering the transition and integrating new assets into existing frameworks.
Strategic Importance of the Purchase
This move is not simply about expanding product offerings; it signifies a broader strategy for BioStem to cement its role as a key player in the regenerative healing sector. By capitalizing on the strengths of BioTissue, BioStem is ensuring that it remains responsive to the evolving needs of healthcare providers and patients alike.
Innovations in Wound Care
BioStem’s commitment to innovation in wound care products reflects a growing trend within the industry to prioritize regenerative medical solutions. This is exemplified through their specialized technology that maximizes therapeutic efficacy while maintaining a focus on patient safety and healing quality.
Conclusion
The acquisition of BioTissue Holdings’ surgical and wound care division represents a pivotal moment for BioStem Technologies. This strategic initiative not only enhances their presence within the healthcare system but also embodies the spirit of entrepreneurial innovation that drives the Florida economy. As local businesses continue to navigate growth opportunities, support for initiatives that promote less regulation and greater market participation can inspire further entrepreneurial success across the Jacksonville business landscape. Engaging with and supporting local businesses like BioStem is imperative for a healthy and robust economic future.
Frequently Asked Questions (FAQ)
What did BioStem Technologies Inc. acquire?
BioStem Technologies Inc. completed a $15 million cash acquisition of BioTissue Holdings’ surgical and wound care division, including the Neox and Clarix product lines.
How will this acquisition impact BioStem’s operations?
The acquisition is expected to enhance BioStem’s presence in hospital inpatient and outpatient care settings and expand its offerings in acute wound care and soft-tissue repair markets.
Who is leading the combined commercial team post-acquisition?
Barry Hassett, formerly Senior Vice President of Commercial Strategy at BioStem, has been promoted to Chief Commercial Officer to lead the combined commercial team.
What is BioStem Technologies’ core business focus?
BioStem Technologies specializes in developing, manufacturing, and commercializing placental-derived products for advanced wound care, utilizing its proprietary BioRetain processing method to preserve the natural properties of perinatal tissue.
Where can I find more information about BioStem Technologies?
More information is available on BioStem Technologies’ official website at www.biostemtechnologies.com.
Key Features of BioStem Technologies’ Acquisition
| Feature | Description |
|---|---|
| Acquisition Value | $15 million cash |
| Acquired Assets | Neox and Clarix product lines |
| Sales Network | Nationwide direct sales representatives and independent sales agents |
| Financial Performance | Acquired assets generated approximately $29 million in sales during 2025 |
| Leadership Change | Barry Hassett promoted to Chief Commercial Officer |
| Strategic Impact | Enhances presence in hospital inpatient and outpatient care settings; expands offerings in acute wound care and soft-tissue repair markets |
Deeper Dive: News & Info About This Topic
HERE Resources
Author: STAFF HERE JACKSONVILLE WRITER
The JACKSONVILLE STAFF WRITER represents the experienced team at HEREJacksonville.com, your go-to source for actionable local news and information in Jacksonville, Duval County, and beyond. Specializing in "news you can use," we cover essential topics like product reviews for personal and business needs, local business directories, politics, real estate trends, neighborhood insights, and state news affecting the area—with deep expertise drawn from years of dedicated reporting and strong community input, including local press releases and business updates. We deliver top reporting on high-value events such as the Jacksonville Jazz Festival, Riverside Arts Market, and World of Nations Celebration. Our coverage extends to key organizations like the Jacksonville Chamber of Commerce and JAXUSA Partnership, plus leading businesses in logistics, healthcare, and entertainment that power the local economy such as CSX Corporation, Baptist Health, and VyStar Credit Union. As part of the broader HERE network, including HEREOrlando.com, HEREStPetersburg.com, HERETallahassee.com, and HERETampa.com, we provide comprehensive, credible insights into Florida's dynamic landscape.
